HETERO LABS LIMITED
Location
Telangana
Founded
1989-03-10
Website
Risk Signals
263 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Pharmaceutical Preparations), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about HETERO LABS LIMITED
Live alerts from global media, monitored by Business Radar
2024-12-24 (oncodaily.com)
FDA Approves Generic Nilotinib: Expanding Access to Chronic Myeloid Leukemia Treatment -
FDA Approves Generic Nilotinib: Expanding Access to Chronic Myeloid Leukemia Treatment / Access to Oncology Medicines Coalition, cancer, chronic myeloid
Read more
2024-10-03 (prnewswire.co.uk)
Hetero Signs Voluntary Licensing Agreement with Gilead to Transform Global HIV response, Expanding Access to Groundbreaking Lenacapavir to 120 high-incidence countries
/PRNewswire/ -- Hetero, India's leading pharmaceutical company with the widest global reach, today announced a new partnership with Gilead Sciences Ireland UC...
Read more
2024-09-26 (realtynmore.com)
91Springboard Expands in Hyderabad with New 48,000 sq. ft Coworking Hub in HITEC City
Hyderabad / September 25, 2024: Managed coworking space provider 91Springboard has announced its third hub in Hyderabad’s HITEC City, marking its 31st location across the country and reinforcing its commitment to delivering personalised workspace solutions.
Read more
2020-06-21 (expresspharma.in)
Hetero announces launch of generic remdesivir ‘COVIFOR’ for COVID-19 treatment
COVIFOR will be available in 100 mg vial (injectable) which has to be administered intravenously in a hospital setting under the supervision of a healthcare practitioner
Read more
2019-04-18 (fda.gov)
Updated: Torrent Pharmaceuticals Limited Expands Voluntary Nationwide Recall of Losartan Potassium Tablets, USP and Losartan Potassium/Hydrochlorothiazide Tablets, USP
Torrent Pharmaceuticals Limited is expanding its recall for Losartan Potassium Tablets USP and Losartan Potassium/hydrochlorothiazide tablets, USP, to the consumer level due to the detection of trace amounts of an unexpected impurity
Read more
(thehindubusinessline.com)
Hetero plans to invest ₹1,000 crore over next 2 years in AP
40 per cent of global HIV drugs are manufactured in AP facility, says Vamsi Krishna Bandi, MD, Hetero
Read more
(telanganatoday.com)
Hetero acquires manufacturing plant at Penjerla, to invest Rs 600 crore and create 2,000 jobs
Hyderabad: Hyderabad-headquartered pharma company Hetero said it acquired a manufacturing plant at Penjerla village of Kothur mandal in Mahbubnagar. The company committed an investment of about Rs.600 crore to upgrade and enhance the existing facilities at the site.
Read more
(economictimes.com)
Hetero to invest Rs 1,000 crore in AP over two years to expand pharma business
"We are committed to Andhra Pradesh and will continue to expand our presence here. We'll be investing about Rs 1,000 crore in Andhra Pradesh over the next two years to grow our pharmaceutical and specialty business. This will generate an employment of a minimum of 3,000 people," he said.
Read more